Contact

Our portfolio

AviSia Therapeutics

Harnessing the power of glycan-mediated immune modulation, AviSia Therapeutics develops antigen-specific immunotherapies for the treatment of autoimmune diseases. The company’s initial focus is on the development of an immune modulating therapeutic for Type 1 Diabetes, for which preclinical proof-of-concept has been shown.

  • Institute: Amsterdam UMC
Industry: Immunology, Therapeutics
  • Founding year: 2024
Visit website

Want to get in contact about AviSia Therapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Quantib
Enhancing patient care with AI-driven radiology solutions for clinical practice.
InspectT
Enabling standard spectrometers to simultaneously measure both chemical composition and particle size by integrating patented, cost-effective Optical-DOSY flow cells.
InSteps
Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.
Confocal NL
Enhancing microscopes with low-power super-resolution imaging solutions.
Quantib
Enhancing patient care with AI-driven radiology solutions for clinical practice.
InspectT
Enabling standard spectrometers to simultaneously measure both chemical composition and particle size by integrating patented, cost-effective Optical-DOSY flow cells.
InSteps
Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.
Confocal NL
Enhancing microscopes with low-power super-resolution imaging solutions.
Explore full AAV portfolio
Contact